Cannabidiol for Epilepsy: New Hope on the Horizon?

Clin Ther. 2018 Sep;40(9):1438-1441. doi: 10.1016/j.clinthera.2018.07.020. Epub 2018 Aug 25.

Abstract

Epilepsy is a common neurologic disorder; it is estimated that ∼50million people are affected worldwide. About one third of those patients are drug resistant, defined as failure to stop all seizures despite adequate trials of at least 2 appropriate medications. There has been an enormous interest in developing antiepileptic drugs with novel mechanisms of action. This review discusses the evidence supporting the anticonvulsant properties of cannabis in humans, focusing on cannabidiol. We begin by exploring the early and somewhat anecdotal evidence that was recently replaced by high-quality data from randomized controlled studies, which subsequently led to the US Food and Drug Administration approval of a purified cannabidiol extract for the treatment of 2 highly refractory pediatric epilepsy syndromes (Dravet and Lennox-Gastaut).

Keywords: cannabidiol; cannabis; epilepsy; marijuana; seizures.

Publication types

  • Review

MeSH terms

  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Cannabidiol / adverse effects
  • Cannabidiol / therapeutic use*
  • Drug Resistant Epilepsy / drug therapy*
  • Drug Therapy, Combination
  • Humans
  • Randomized Controlled Trials as Topic
  • Seizures / drug therapy

Substances

  • Anticonvulsants
  • Cannabidiol